Equity Profile

ARWR

Arrowhead Pharmaceuticals, Inc.

Health CareBiotechnology$10.4B

Aug6Thu

Pre-Earnings Brief

UpcomingQ3-2026After Close5:00 PM EDT

Company Snapshot

Arrowhead Pharmaceuticals, Inc. is a biotechnology company focused on developing medicines to treat serious diseases by using RNA interference technology....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of profitability, and investors will be looking for signs of improvement or continued losses.

N/A

Revenue Growth

Revenue growth is crucial for assessing the company's ability to scale its operations and attract investors.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

ARWR Q3-2026 Earnings Preview

Context

Company Snapshot

Arrowhead Pharmaceuticals, Inc. is a biotechnology company focused on developing medicines to treat serious diseases by using RNA interference technology. With a market cap of $10 billion, it operates in the health care sector, which is increasingly important as new therapies are sought for various conditions.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

25%

Avg EPS Surprise

+322.88%

Avg Stock Reaction

+0.59%

Last Quarter Recap

In Q2 2026, Arrowhead reported an EPS of -$0.93, which was better than the expected -$1.18, resulting in a positive surprise. However, the stock fell 1.50% the next day, indicating mixed investor sentiment.

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall, the market appears cautious ahead of the earnings report, with no analyst estimates available and a history of mixed performance.

Bull Case

If Arrowhead can show significant progress in its drug pipeline or better-than-expected EPS, it could lead to a strong positive reaction from investors.

Bear Case

Conversely, if the company reports wider losses or fails to provide any positive guidance, it may lead to further declines in stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will be the EPS for Q3-2026?

Given the company's recent history of earnings surprises, this figure will heavily influence investor sentiment.

What updates can management provide on the drug pipeline?

Any positive developments or setbacks in the pipeline could significantly impact future revenue and investor confidence.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for a turnaround in Arrowhead's drug pipeline, which could yield better-than-expected results.

Supporting Evidence

The company's recent EPS surprise of +20.85% suggests potential for further positive surprises.

Options pricing indicates a significant expected move, reflecting uncertainty that could lead to a larger reaction.

Key Risk

If the EPS comes in better than expected, it could challenge the current cautious outlook.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance is critical as it follows a pattern of mixed results, and investors are eager for clarity on profitability and growth.

Bull Confirmed If

A positive EPS surprise of at least $0.10 would confirm the bull case.

Bear Confirmed If

An EPS loss greater than $1.00 would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±21.53%

Historical Avg

±3.5%

Pricing rich

The options market is pricing in a significant move, suggesting that investors expect volatility around the earnings announcement.

Options are pricing ±21.5% while ARWR has averaged ±3.5% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.7%

30d HV

50.9%

Calls (20K)P/C Ratio: 0.16Puts (5K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Arrowhead beats expectations, history suggests a potential average one-day move of +2.86%, confirming a positive outlook.

In-Line / Cautious

If results are in line with expectations, the stock may see muted reactions as investors await further guidance.

Miss

A miss could lead to a decline, with history indicating an average one-day move of -0.17% when expectations are not met.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on the status of ongoing clinical trials.
2Management's commentary on cost management and operational efficiency.
3Insights into partnerships or collaborations that could enhance growth.
4Details on any upcoming product launches or regulatory approvals.
5Guidance on future revenue expectations and market conditions.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Danaos Corporation

Company Snapshot

Arrowhead Pharmaceuticals, Inc. is a biotechnology company focused on developing medicines to treat serious diseases by using RNA interference technology....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of profitability, and investors will be looking for signs of improvement or continued losses.

N/A

Revenue Growth

Revenue growth is crucial for assessing the company's ability to scale its operations and attract investors.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

ARWR Q3-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

25%

Avg EPS Surprise

+322.88%

Avg Stock Reaction

+0.59%

Last Quarter Recap

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall, the market appears cautious ahead of the earnings report, with no analyst estimates available and a history of mixed performance.

Bull Case

If Arrowhead can show significant progress in its drug pipeline or better-than-expected EPS, it could lead to a strong positive reaction from investors.

Bear Case

Conversely, if the company reports wider losses or fails to provide any positive guidance, it may lead to further declines in stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will be the EPS for Q3-2026?

Given the company's recent history of earnings surprises, this figure will heavily influence investor sentiment.

What updates can management provide on the drug pipeline?

Any positive developments or setbacks in the pipeline could significantly impact future revenue and investor confidence.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for a turnaround in Arrowhead's drug pipeline, which could yield better-than-expected results.

Supporting Evidence

The company's recent EPS surprise of +20.85% suggests potential for further positive surprises.

Options pricing indicates a significant expected move, reflecting uncertainty that could lead to a larger reaction.

Key Risk

If the EPS comes in better than expected, it could challenge the current cautious outlook.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance is critical as it follows a pattern of mixed results, and investors are eager for clarity on profitability and growth.

Bull Confirmed If

A positive EPS surprise of at least $0.10 would confirm the bull case.

Bear Confirmed If

An EPS loss greater than $1.00 would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±21.53%

Historical Avg

±3.5%

Pricing rich

The options market is pricing in a significant move, suggesting that investors expect volatility around the earnings announcement.

Options are pricing ±21.5% while ARWR has averaged ±3.5% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.7%

30d HV

50.9%

Calls (20K)P/C Ratio: 0.16Puts (5K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Arrowhead beats expectations, history suggests a potential average one-day move of +2.86%, confirming a positive outlook.

In-Line / Cautious

If results are in line with expectations, the stock may see muted reactions as investors await further guidance.

Miss

A miss could lead to a decline, with history indicating an average one-day move of -0.17% when expectations are not met.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on the status of ongoing clinical trials.
2Management's commentary on cost management and operational efficiency.
3Insights into partnerships or collaborations that could enhance growth.
4Details on any upcoming product launches or regulatory approvals.
5Guidance on future revenue expectations and market conditions.